These findings corroborate previous evidence showing reduced expression of CD80 in many cancer types (i.e., melanoma, myeloma, acute myeloid leukemia, bladder, and colon carcinoma) and are in agreement with the observation of its lower expression in poorer differentiated esophageal cancers, compared to well- and moderate-differentiated ones [21, 52, 53]. Here, CD80 is linked to esophageal cancer.